Cargando…
New Insights in the Setting of Transplant Oncology
Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developme...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058845/ https://www.ncbi.nlm.nih.gov/pubmed/36984569 http://dx.doi.org/10.3390/medicina59030568 |
_version_ | 1785016732713222144 |
---|---|
author | Quaresima, Silvia Melandro, Fabio Giovanardi, Francesco Shah, Kejal De Peppo, Valerio Mennini, Gianluca Ghinolfi, Davide Limkemann, Ashley Pawlik, Timothy M. Lai, Quirino |
author_facet | Quaresima, Silvia Melandro, Fabio Giovanardi, Francesco Shah, Kejal De Peppo, Valerio Mennini, Gianluca Ghinolfi, Davide Limkemann, Ashley Pawlik, Timothy M. Lai, Quirino |
author_sort | Quaresima, Silvia |
collection | PubMed |
description | Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). Materials and Methods: A review of the recently published literature was conducted. Results: Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. Conclusion: For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT’s impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required. |
format | Online Article Text |
id | pubmed-10058845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100588452023-03-30 New Insights in the Setting of Transplant Oncology Quaresima, Silvia Melandro, Fabio Giovanardi, Francesco Shah, Kejal De Peppo, Valerio Mennini, Gianluca Ghinolfi, Davide Limkemann, Ashley Pawlik, Timothy M. Lai, Quirino Medicina (Kaunas) Review Background and Objectives: Liver transplantation (LT) is the best strategy for curing several primary and secondary hepatic malignancies. In recent years, growing interest has been observed in the enlargement of the transplant oncology indications. This paper aims to review the most recent developments in the setting of LT oncology, with particular attention to LT for unresectable colorectal liver metastases (CRLM) and cholangiocellular carcinoma (CCA). Materials and Methods: A review of the recently published literature was conducted. Results: Growing evidence exists on the efficacy of LT in curing CRLM and peri-hilar and intrahepatic CCA in well-selected patients when integrating this strategy with (neo)-adjuvant chemotherapy, radiotherapy, or locoregional treatments. Conclusion: For unresectable CCA and CRLM management, several prospective protocols are forthcoming to elucidate LT’s impact relative to alternative therapies. Advances in diagnosis, treatment protocols, and donor-to-recipient matching are needed to better define the oncological indications for transplantation. Prospective, multicenter trials studying these advances and their impact on outcomes are still required. MDPI 2023-03-14 /pmc/articles/PMC10058845/ /pubmed/36984569 http://dx.doi.org/10.3390/medicina59030568 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Quaresima, Silvia Melandro, Fabio Giovanardi, Francesco Shah, Kejal De Peppo, Valerio Mennini, Gianluca Ghinolfi, Davide Limkemann, Ashley Pawlik, Timothy M. Lai, Quirino New Insights in the Setting of Transplant Oncology |
title | New Insights in the Setting of Transplant Oncology |
title_full | New Insights in the Setting of Transplant Oncology |
title_fullStr | New Insights in the Setting of Transplant Oncology |
title_full_unstemmed | New Insights in the Setting of Transplant Oncology |
title_short | New Insights in the Setting of Transplant Oncology |
title_sort | new insights in the setting of transplant oncology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058845/ https://www.ncbi.nlm.nih.gov/pubmed/36984569 http://dx.doi.org/10.3390/medicina59030568 |
work_keys_str_mv | AT quaresimasilvia newinsightsinthesettingoftransplantoncology AT melandrofabio newinsightsinthesettingoftransplantoncology AT giovanardifrancesco newinsightsinthesettingoftransplantoncology AT shahkejal newinsightsinthesettingoftransplantoncology AT depeppovalerio newinsightsinthesettingoftransplantoncology AT menninigianluca newinsightsinthesettingoftransplantoncology AT ghinolfidavide newinsightsinthesettingoftransplantoncology AT limkemannashley newinsightsinthesettingoftransplantoncology AT pawliktimothym newinsightsinthesettingoftransplantoncology AT laiquirino newinsightsinthesettingoftransplantoncology |